CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.37M | 28.02M | 47.98M | 41.60M | 31.87M |
| Total Depreciation and Amortization | 1.38M | 1.28M | 1.57M | 1.69M | 1.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.98M | 8.92M | 8.84M | 8.16M | 6.55M |
| Change in Net Operating Assets | -68.58M | -110.47M | -135.83M | -132.67M | -126.42M |
| Cash from Operations | -75.59M | -72.25M | -77.43M | -81.23M | -86.23M |
| Capital Expenditure | -220.00K | -99.00K | -245.00K | -314.00K | -310.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.52M | -30.09M | -12.22M | 85.73M | 100.01M |
| Cash from Investing | -59.74M | -30.19M | -12.46M | 85.41M | 99.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 110.45M | 96.05M | 95.80M | 7.35M | 7.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 110.45M | 96.05M | 95.80M | 7.35M | 7.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.89M | -6.39M | 5.91M | 11.53M | 20.99M |